Uma Mahadevan, MD completed a medical degree at the State University of New York in Brooklyn. She completed residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF) and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF, Medical Director of the UCSF Center for Colitis and Crohn’s Disease and Director of the IBD Fellowship. She is the Ambulatory Clinical Services Chief for Gastroenterology. Certified by the American Board of Internal Medicine as a Diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she is Chair for the Clinical Immunology, Microbiology and Inflammatory Bowel Disease (IMIBD) Section and co-director of the 2017 Post-Graduate Course. She is also a fellow of the American College of Gastroenterology for whom she was Chair of IBD for the 2017 ACG/World Congress course and a member of the Educational Affairs Committee. She is currently Chair of the Crohn's Colitis Foundation Clinical Research Grants committee and a member of the CCF National Scientific Advisory Committee. She was elected to the International Organization of IBD (IOIBD) in 2018. Dr. Mahadevan is an special section editor for Gastroenterology and an editorial board member and reviewer for several other journals. She was the editor of a special issue on IBD for 2017. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, Gut, American Journal of Gastroenterology and Inflammatory Bowel Diseases along with several book chapters. Dr. Mahadevan specializes in the treatment of ulcerative colitis, Crohn’s disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, nutritional therapies for IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn’s disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and microbiome, environmental and dietary changes among patients with IBD.